In our opinion, although many clinical trials regarding MSLN-targeting therapies in ovarian carcinomas are ongoing, further studies will be useful for providing other satisfactory results and for establishing their effects on the health and behavioural outcomes of patients. The gene discussed is MSLN; the disease is ovarian carcinoma.